ArticleGastro hep advances2026
Blood Biomarkers of Glucose Metabolism and Liver Function Modestly Improve Prediction of High-Risk Adenomas.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Colonoscopy is an effective screening tool, but it is resource-intensive and carries procedural risks. We aimed to develop and validate a biomarker-based risk prediction model (RPM) to improve triage of average-risk patients for colonoscopy by better predicting high-risk adenomas (HRAs). Methods: We assessed blood-based biomarkers of glucose metabolism, liver enzymes, lipids, ferritin, and carcinoembryonic antigen (CEA) in 980 average-risk individuals undergoing screening colonoscopy. Logistic regression was used to predict HRAs, defined as adenomas ≥10 mm, villous histology, high-grade dysplasia, or ≥3 adenomas. Biomarkers were modeled as continuous variables; variable selection was performed using logistic regression and least absolute shrinkage and selection operator. Model performance was evaluated with area under the curve, reclassification indices, calibration statistics, bootstrap validation, and decision curve analysis. Results: Glucose and CEA were significantly associated with HRAs, while no biomarkers were linked to high-risk sessile serrated lesions. Nine RPMs were developed; 3 were selected for validation. A model including all univariately associated biomarkers (CEA, C-peptide, gamma-glutamyl transferase, glucose, hemoglobin A1c, triglycerides) achieved an optimism-adjusted area under the curve of 0.66 (95% confidence interval, 0.60-0.71). Reclassification indices showed that adding biomarkers improved stratification, with the all-biomarkers model yielding the highest net reclassification improvement. Conclusion: Biomarker-enhanced RPMs modestly improved prediction of HRAs compared with models using only clinical and demographic variables. These findings support the potential of biomarkers to optimize colonoscopy resource allocation, but additional markers and refinement are needed to establish clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.